What Insmed Stock’s Premium Is Actually Buying

Insmed (INSM) stock trades at a significant premium, 25.3 times sales, despite being 37% below its 52-week high, with this premium driven by an optimistic peak-sales estimate of over $14 billion. This estimate relies heavily on the future success of TPIP, a drug still in Phase III trials, rather than solely on its currently selling drugs like BRINSUPRI and ARIKAYCE. The company aims for cash flow positivity by 2027 without raising capital, but faces risks including TPIP's trial outcomes and the sustainability of patient starts for BRINSUPRI.